Charles River Labs Intl Stock
Price
Target price
€141.05
€141.05
3.640%
5.05
3.640%
€165.88
24.02.26 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
Charles River Labs Intl dominated the market today, gaining €5.05 (3.640%).
With 22 Buy predictions and not a single Sell prediction Charles River Labs Intl is an absolute favorite of our community.
As a result the target price of 165 € shows a slightly positive potential of 16.98% compared to the current price of 141.05 € for Charles River Labs Intl.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 3.640% | 3.523% | -24.085% | -11.261% | -18.303% | -32.350% | -39.203% |
| Iovance Biotherapeutics Inc. | -5.230% | 39.741% | 44.943% | -36.413% | 36.235% | -51.347% | -89.243% |
| United Therapeutics | -5.910% | 11.714% | 14.700% | 33.715% | 6.459% | 92.103% | 224.929% |
| Neurocrine Bioscience | 0.990% | 3.013% | -3.559% | 0.725% | -8.972% | 14.383% | 22.330% |
Comments
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Show more
Ratings data for CRL provided by MarketBeat